Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of AVM Biotechnology.

    Client Virtual Booth

    AVM BIOTECHNOLOGY

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    SERVICES

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    AVM Biotechnology
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1749 Dexter Ave N, Seattle, WA 98109
    Telephone
    Telephone
    1(206)906-9922
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://avmbiotech.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/avm-biotechnology/
    Twitter
    Twitter
    https://twitter.com/avmbiotech?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AVM Biotechnology Announces Twenty-Eight (28) Solid Tumor and Blood Cancer Patients Have Been Treated with Immunomodulatory AVM0703 Through Expanded Acc...

    Details:

    AVM0703 is small molecule immunomodulatory drug enrolling Phase 2 trials in US in relapsed/refractory Non-Hodgkin's Lymphoma (NHL) which began enrollment Q3 2023 (partially funded by NCI Ph II FastTrak grant 1R44CA272096).


    Lead Product(s): Dexamethasone Sodium Phosphate

    Therapeutic Area: Oncology Product Name: AVM0703

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 01, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AVM Biotechnology Awarded $2 Million National Cancer Institute SBIR Phase II Grant from the National Institutes of Health to Advance AVM0703 in Cancer

    Details:

    AVM0703 (Dexamethasone sodium phosphate) is a small molecule which triggers the production and release of endogenous bispecific gamma delta TCR+ invariant TCR+ Natural Killer T-like cells (AVM-NKT).


    Lead Product(s): Dexamethasone Sodium Phosphate

    Therapeutic Area: Oncology Product Name: AVM0703

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: National Cancer Institute

    Deal Size: $2.0 million Upfront Cash: Undisclosed

    Deal Type: Funding June 14, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AVM Biotechnology to Present Poster Highlighting the Effects of AVM0703 Against Solid Tumors and Blood Cancers at the 2022 ASCO Annual Meeting

    Details:

    AVM0703 (dexamethasone) led to, complete response in 27% of immune-resistant mouse A20 tumors as monotherapy and complete response in 60% when combined with 2 doses of cyclophosphamide/fludarabine (CyFlu).


    Lead Product(s): Dexamethasone Sodium Phosphate

    Therapeutic Area: Oncology Product Name: AVM0703

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 01, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AVM Biotechnology Founder and CSO to Present Company Information and Clinical Trial Progress at Life Science Innovation Northwest

    Details:

    AVM0703 is a small molecule which triggers the production and release of endogenous bispecific gamma delta TCR+ and invariant TCR+ Natural Killer T-like cells (AVM-NKT).


    Lead Product(s): Dexamethasone

    Therapeutic Area: Oncology Product Name: AVM0703

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 19, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AVM Biotechnology Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes

    Details:

    T1D is an autoimmune disease that destroys beta cells, the insulin-making cells in the pancreas. This award provides an endorsement of AVM0703’s potential in two distinct and crucial therapeutic areas, diabetes and cancer.


    Lead Product(s): Dexamethasone

    Therapeutic Area: Endocrinology Product Name: AVM0703

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: National Institute of Diabetes and Digestive Kidney Disease

    Deal Size: $1.6 million Upfront Cash: Undisclosed

    Deal Type: Funding April 05, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Seattle AVM Biotechnology Announces Second IND for AVM0703

    Details:

    This second study will evaluate AVM0703 in two different ARDS patient populations: one with COVID-19-mediated moderate to severe ARDS and the other with Influenza-mediated severe ARDS.


    Lead Product(s): Dexamethasone Sodium Phosphate

    Therapeutic Area: Infections and Infectious Diseases Product Name: AVM0703

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 16, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AVM Biotechnology Awarded SBIR Phase I Grant from National Cancer Institute

    Details:

    AVM Biotechnology has been awarded a National Cancer Institute Small Business Innovation Research Grant from the NIH to study the use of AVM0703 as a preconditioning agent to allow safe and efficient delivery of therapeutic immune cells for cancer treatment.


    Lead Product(s): Dexamethasone Sodium Phosphate,Hydrocortisone,Undisclosed

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 11, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    AVM Biotechnology has FDA Approval for Clinical Trials for Promising New Cancer Treatment

    Details:

    AVM Biotechnology received clinical trial approval for AVM0703. Unlike chemotherapy and radiation, AVM0703 spares platelets and red blood cells, limiting the need for transfusions.


    Lead Product(s): Dexamethasone Sodium Phosphate

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 14, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search